secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001493152-23-022852
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Semper Paratus Acquisition Corp. enters definitive merger with Tevogen Bio at $1.2B enterprise value
--------------------------------------------------------------------------------

- Merger consideration: $1.2B in Semper Paratus Class A common stock; plus up to 20M earnout shares at price targets of $15, $17.50, $20.
- Post-closing board: 7 directors, 6 designated by Tevogen Bio; CEO and CFO of Tevogen to continue in same roles.
- Closing conditions: minimum $25M cash at close, shareholder approvals, SEC registration, and $5M net tangible assets.
- Outside date: December 5, 2023; no termination fees; equity line of credit $35M-$60M possible but not required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/0001493152-23-022852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer